Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal cenegermin in pediatric spastic cerebral palsy
2025-522786-29-00Phase 2Authorised
- Sponsor
- Dompé
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenegermin in cerebral palsy (CP) (2 arms), sponsored by Dompé. Primary endpoint: Incidence of treatment-emergent adverse events following the first administration of investigational product. Planned start Dec 2025; status: authorised.
02
Drugs
cenegermin
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on 2025-522786-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522786-29-00.